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Abstract Tongue cancer has a poor prognosis due to its
early metastasis via lymphatic vessels. The present study
aimed at evaluating lymphatic vessel density, relative
density of lymphatic vessel, and diameter of lymphatic
vessels and its predictive role in tongue cancer. Paraffin-
embedded tongue and lymph node specimens (n = 113)
were stained immunohistochemically with a polyclonal
antibody von Willebrand factor, recognizing blood and
lymphatic endothelium and with a monoclonal antibody
podoplanin, recognizing lymphatic endothelium. The
relative density of lymphatic vessels was counted by
dividing the mean number of lymphatic vessels per
microscopic field (podoplanin) by the mean number of all
vessels (vWf) per microscopic field. The high relative
density of lymphatic vessels (C80 %) was associated with
poor prognosis in tongue cancer. The relative density of
lymphatic vessels predicted poor prognosis in the group of
primary tumor size T1–T2 and in the group of non-meta-
static cancer. The lymphatic vessel density and diameter of
lymphatic vessels were not associated with tongue cancer
survival. The relative density of lymphatic vessels might
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have clinically relevant prognostic impact. Further studies
with increased number of patients are needed.
Keywords Tongue cancer  Head and neck cancer 
Lymphatic vessels  Survival  Immunohistochemistry
Introduction
Tongue squamous cell carcinoma (tongue cancer) accounts
for more than half of the total oral cancer cases diagnosed
each year worldwide [1]. Tongue cancer is one of the most
aggressive cancers in the oral cavity [1]. Its 5-year survival
rate is only about 50 % [2]. Lymph node metastasis
strongly correlates with the survival in patients with oral
cancer [3]. The incidence of neck lymph node metastasis in
oral cancer varies from 25 to 65 % [4, 5]. Tongue cancer
typically metastasizes to cervical lymph nodes [6] due to
the presence of a rich lymphatic network and the high
number of lymph nodes in the neck region [3, 7, 8]. Tumor
cells are able to migrate to lymphatic vessels and, there-
fore, migrate to the lymph nodes [9]. Blocking the lym-
phangiogenesis of the tumor might be important in
preventing the metastatic cascade of the cancer. Thus,
understanding the pathophysiology of lymph node metas-
tasis in tongue cancer is essential for early diagnosis and
treatment.
Quantification of blood and lymphatic vessel density
has been used to understand the cancer biology and as a
prognostic factor, for example, in melanoma and head and
neck cancer [10, 11]. There are several antibodies which
recognize blood and/or lymphatic vessel antigens. Von
Willebrand factor (vWf) is a large glycoprotein with a
multimeric structure which mass ranging from 500 kDa
up to over 10 000 kDa [12]. The encoding gene of vWf is
located in chromosome 12p13.2 [13]. vWf is produced
through a multiphase process by endothelial cells and
megakaryocytes [13]. The primary product of the gene is
a 2813 amino acids protein which is composed of a signal
peptide of 22 amino acids, a large propeptide of 741
amino acids, and a mature vWF molecule containing 2050
amino acids [12]. vWf is expressed by blood endothelium
and also weakly expressed on lymphatic endothelium
[14–19]. Results about vWf expression in cancers are
ambivalent [20]. Studies have shown that colorectal and
gastric cancers have a higher density of vWf stained
vessels than healthy tissue. The high density of vessels
correlates with poor survival [13, 21]. In contradiction,
previous experimental studies have demonstrated that
vWf could reduce metastases by inducing tumor cell
death [22]. In addition, vWf might have pro-apoptotic
properties, thus its deficiency enhances metastatic poten-
tial in mice [23].
Monoclonal antibody podoplanin (clone D2-40) recog-
nizes podoplanin in lymphatic endothelium. D2-40 was
originally recognized as an oncofetal antigen, M2A antigen,
which is anO-linked sialoglycoprotein with a simple mucin-
type carbohydrate epitope associated with germ-cell neo-
plasms [24, 25]. Currently, it is known that podoplanin and
M2A antigen are identical proteins [25]. Podoplanin is
expressed in lymphatic endothelial cells, but is not expressed
in blood endothelial cells [26]. Therefore, it is a specific
marker for lymphatic endothelium [26]. The overexpression
of podoplanin has been reported in oral premalignacies, such
as oral leukoplakia, oral erythroleukoplakia, carcinoma
in situ, and lichen planus [27–31].
Tongue cancer is often aggressive, invasive, and has
high tumor growth capacity which generates the consid-
erable risk of lymphatic invasion by tumor cells [32, 33].
Lymphangiogenesis, richness of lymphatic vessels, and
muscularized structures have shown to be crucial in pro-
gression of tongue cancer [34]. To understand more of
these pathways, this study aimed at evaluating lymphatic
vessel density, lymphatic vessel diameter, the relative
density of lymphatic vessels, and its predictive role in
tongue cancer. We hypothesized that lymphatic vessel
density associates with tongue cancer survival.
Materials and methods
Clinical samples
This study was performed at the Departments of Otorhi-
nolaryngology and Pathology, Tampere University Hospi-
tal and Haartman Institute, University of Helsinki, Finland.
The study protocol was approved by the Hospital’s Ethical
Committee. The formalin-fixed paraffin-embedded samples
were collected retrospectively from the archives of the
hospital. The samples were taken from 61 patients who had
been treated for tongue squamous cell carcinoma during
the years 1999–2007. The control group consisted of 29
patients who had been treated for tongue squamous cell
hyperplasia during the same time interval. All samples
were reviewed by a pathologist. The demographic data,
collected from patient records, are shown in Table 1. The
power analysis was performed by approximated 75 %
increase in median lymphatic vessel density in the non-
surviving group. With approximated standard deviation of
1.0, the estimated sample size was 56 (a = 0.05, b = 0.2).
Tissue handling and immunohistochemistry
Von Willebrand factor and podoplanin staining were per-
formed on 113 samples. Before performing immunohisto-
chemistry, the pathologist (TP) reviewed all samples by
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light microscope and selected the samples with the most
representative pathological signs of cancer or hyperplasia
with no or very little necrosis. The samples were cut into
4–5 lm-thick paraffin sections and were placed on
Superfrost Plus microscope slides (Menzel-Gla¨ser, Braun-
schweig, Germany). Fully automated immunostaining was
performed by Ventana BenchMark LT Automated IHC
Stainer (Ventana Medical System, Tucson, Arizona, USA).
Ultraview Universal DAB detection kit (catalog no.
760-500, Ventana Medical System) was used. Ventana EZ
Prep solution (catalog no. 950-100, Ventana Medical
System) was used for deparaffinisation. For epitope
retrieval CC1: Tris-EDTA buffer pH 8.0 (catalog no.
950-124, Ventana Medical System) was used at 95 to
100 C for 30 min with paraffin-embedded tissue sections.
Endogenous peroxidase was blocked with UV-inhibitor
3 % H202 (Ventana Medical System) for 4 min at 37 C.
Tissue slides were rinsed between steps with Ventana Tris-
based Reaction buffer (catalog no. 950-300, Ventana
Medical System). Slides were incubated at 37 C for
24 min with pAb anti-Von Willebrand factor (1:2000,
A0082, DAKO Corporation, Carpinteria, CA, USA), and
for 32 min with mAb anti-podoplanin (1:50, Clone D2-40,
M3619, DAKO Corporation, Carpinteria, CA, USA) fol-
lowed by the application of Ventana Ultraview HRP
Universal Multimer (8 min at 37 C). Diaminobenzidine
(DAB) was used as a chromogen and hematoxylin as a
nuclear stain. The known positive tissue samples from
sinonasal mucosa were also used to confirm the staining
reliability of all separate staining patches. Specificity of
immunohistochemistry was controlled by omitting the
primary antibodies or replacing them with irrelevant
antisera.
Light microscopic evaluation
Cytoplasmic staining of lymphatic and blood endothelial
cells were examined with a Leica DM 2000 light micro-
scope (Leica Microsystems GmbH, Wetzlar, Germany) by
two observers without knowledge of clinical status and
outcome data.
In the tongue cancer specimens, the vessel density was
calculated in intratumoral area and whole tumor (including
intra- and peritumoral) from five microscopic fields
(0.785 mm2/field). The relative density of lymphatic vessels
(RDLV) was counted by dividing the mean number of
lymphatic vessels per microscopic field (podoplanin) by the
mean number of all vessels (vWf) per microscopic field.
vWF is weakly expressed on lymphatic endothelium.
Therefore, the positive lymphatic vessel staining of vWfwas
assured by the lack of erythrocyte or smooth muscle within
the lymphatic vessel walls. Analysis was performed at 2009
(209 objective lens and 109 ocular lens) magnification.
The mean diameters of lymphatic vessels were deter-
mined in five fields with 400 (409 objective lens and 109
ocular lens) magnification in intratumoral area and whole
tumor. The mean diameter of the samples was graded as
S B 50 lm, M = 51–130 lm, L\ 130 lm.
Data analysis
Descriptive statistics for patients and tumor characteristics
were presented in tongue cancer and in tongue hyperplasia.
Fisher’s exact test (2-tailed) was used to compare patient
and tumor characteristics. The correlations were analyzed
by the Spearman rank correlation test. The Kruskal–Wallis
test (more than two groups) and Mann–Whitney U test
Table 1 Characteristics of the
patients
Tongue hyperplasia, n = 29 Tongue cancer, n = 61 p value
n % n %
Gender
Male 17 58.6 33 54.1 0.821
Female 12 41.4 28 45.9
Age
\60 years 19 65.6 27 44.3 0.073
C60 years 10 34.5 34 55.7
Smokers
No 22 75.9 29 47.5 0.013
Yes 7 24.1 32 52.5
Heavy alcohol users
No 24 85.7 44 72.1 0.189
Yes 4 14.3 17 27.9
Previous lichen ruber planus 2 6.9 11 18.0 0.033
p values by Fisher’s exact test
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(two groups) were used to study the comparison of the
vessels densities, the relative density of lymphatic vessels,
and diameters of lymphatic vessels in the different groups.
Survival curves were drawn by the Kaplan–Meier method,
and analyzed by the log-rank test. Overall, survival was
calculated from the date of diagnosis to death, while dis-
ease-specific survival was calculated from date of diagno-
sis to death from tongue cancer or the end of June 2014
whichever came first. Two-tailed p-values of\0.05 were
considered statistically significant. Statistical analysis was
carried out by the SPSS Base 15.0 Statistical Software
Package (SPSS Inc., Chicago, IL, USA).
Results
Patient and tumor characteristics
The average age of the patients in the tongue hyperplasia
group was 56 years (min–max 31–82 years) and in the
tongue carcinoma group, it was 61 years (min–max
17–91 years). The difference was not statistically signifi-
cant (Table 1). The number of smokers and patients with
previously diagnosed lichen ruber planus in the oral
mucosa was higher in the tongue cancer group than the
tongue hyperplasia group (Table 1). No significant differ-
ences in other demographic factors were found.
The characteristics of the tumors are shown in Table 2.
32.8 % of tongue cancer patients had tumor size over 4 cm
(T3–T4), 50.8 % had cervical lymph node metastasis,
63.9 % had tumor depth of at least 4 mm, 3.3 % had per-
ineural invasion, and 19.7 % had poorly differentiated
cancer (grade III). 88.5 % of tongue cancer patients
underwent operation. 54.1 % received chemoradiotherapy.
85.2 % of the operated patients underwent additional cer-
vical lymph node management. Growth into one resection
margin was detected in 5.6 % of all resected tumors.
Cancer recurrence occurred in 47.5 % of cases. 36.1 % of
tongue cancer patients were alive after 5 years of follow-
up.
The lymphatic and blood vessel density in tongue
hyperplasia and tongue cancer
Figure 1 shows von Willebrand factor and podoplanin
expression in tongue specimens. In the whole tumor, the
mean density of all vessels (vWf) was 35.7/field in the
tongue hyperplasia group and 30.6/field in the tongue cancer
group. The difference was not statistically significant
(Table 3). The mean density of lymphatic vessels was
15.3/field in the tongue hyperplasia group and 16.6/field in
the tongue cancer group. The difference was not statistically
Table 2 Characteristics of the tumors
Tongue cancer, n = 61
n %
Primary tumor size
T1 14 23.0
T2 27 44.3
T3 17 27.9
T4 3 4.9
cN classification
cN0 44 72.1
cN1 12 19.7
cN2 5 8.2
pN classification
pN0 19 31.1
pN1 7 11.5
pN2 20 32.8
pNx 15 24.6
Cervical LN metastasisa
LN- 30 49.2
LN? 31 50.8
Tumor operation
Resection 20 32.8
Resection and flap reconstructionb 34 55.7
Inoperable 7 11.5
Cervical lymph node management
No 15 24.6
Functionalc 44 72.1
Radical 2 3.3
Resection margin
Clear (C3 mm) 33 54.1
Close (\3 mm) 18 29.5
Involved 3 4.9
Unknown 7 11.5
Tumor grade
I 24 39.3
II 25 41.0
III 12 19.7
Perineural invasion
No 57 93.4
Yes 2 3.3
Unknown 2 3.3
Lymphatic vessel invasion
No 58 93.4
Yes 1 1.6
Unknown 2 3.3
Tumor depth
Low (\4 mm) 7 11.5
High (C4 mm) 39 63.9
Unknown 15 24.6
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significant (Table 3). When observing density of all vessels,
and lymphatic vessels in the subgroups of primary tumor
diameter, tumor grades, cervical lymph node metastasis,
perineural invasion, tumor depth, or 5-year mortality, a
significant difference was not found (Table 3).
In intratumoral area, the mean density of all vessels was
33.2/field and the mean density of lymphatic vessels was
22.9/field. When observing the mean density of all vessels
and lymphatic vessels in the subgroups of primary tumor
sizes, tumor grades, and cervical lymph node metastasis, a
significant difference was not found. The mean density of
all vessel and lymphatic vessel in intratumoral area was
significantly higher than in whole tumor (p = 0.037,
p = 0.001, retrospectively, data not shown).
The lymphatic vessels diameter in tongue cancer
and tongue hyperplasia
The mean diameter of lymphatic vessels was 67 lm
(min–max 13–182 lm) in tongue cancer and 60 (min–
max 13–150) in tongue hyperplasia. The diameter of
lymphatic vessels did not differ between the tongue
hyperplasia group and the tongue cancer group. The
diameter of lymphatic vessels in whole tumor and intra-
tumoral area did not differ in the subgroups of primary
tumor size, tumor grade, and cervical lymph node
metastasis. When comparing the cancer subgroups with
RDLV C80 % and \80 %, the diameter of lymphatic
vessel in the whole tumor area, or in the intratumoral
area, did not differ significantly.
Table 2 continued
Tongue cancer, n = 61
n %
Chemotherapy
No 28 45.9
Yes 33 54.1
Recurrence
No 32 52.5
Yes 29 47.5
Status (5 years of follow-up)
Alive 22 36.1
Dead of tongue cancer 27 44.3
Dead of other causes 12 19.7
a Positive cervical lymph node metastasis (LN?) was determined by
pN?; or cN? in case of pNx
b Microvascular reconstruction by radial forearm flap
c Includes removal of sentinel lymph nodes
Fig. 1 Von Willebrand factor and podoplanin (clone D2-40) expres-
sion in tongue specimens by immunohistochemical methods. The
upper row detects all vessels stained by von Willebrand factor and the
lower row detects lymphatic vessels stained by podoplanin. a\80 %
relative density of lymphatic vessel in tongue hyperplasia. b\80 %
relative density of lymphatic vessel in tongue cancer. c C80 %
relative density in tongue cancer. Original magnification was 2009
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The relative density of lymphatic vessels in tongue
hyperplasia and tongue cancer
The mean RDLV was 50 % in the tongue hyperplasia
group and 62.5 % in the tongue cancer group. The differ-
ence was not statistically significant (Table 3). The median
RDLV was statistically significantly higher in the subgroup
of tumor depth of C4 mm, compared to the group having
tumor depth of\4 mm (Table 3). When comparing RDLV
in the subgroups based on primary tumor size, tumor
grades, cervical lymph node metastasis, perineural inva-
sion, or 5-year mortality, a significant difference was not
found (Table 3). Similarly, when comparing intratumoral
RDLV in the subgroup based on primary tumor size, tumor
grade, and cervical lymph node metastasis, no significant
difference was detected.
The prognostic relevance of relative density
of lymphatic vessels in tongue cancer
In the present study, RDLV was associated with poor
survival in tongue cancer (Fig. 2). When observing all
cancer patients, RDLV C80 % predicted poor overall
and disease-specific survival (Fig. 2a, b). When observ-
ing the subgroup of patients with primary tumor size
T1–T2, RDLV C80 % predicted poor overall and
Table 3 Median values of vessels densities and relative densities of lymphatic vessel by characteristics of the patients
All vessels (N) p value Lymphatic
vessels (N)
p value RDLV (%) p value
Diagnosis 0.207 0.959 0.300
Hyperplasia 35.7 15.3 50.0
Cancer 30.6 16.6 62.5
Primary tumor size 0.991 0.856 0.775
T1 29.9 15.3 52.5
T2 35.7 16.6 70.5
T3 30.6 19.1 58.8
T4 25.5 33.1 74.3
Grade 0.565 0.257 0.443
I 30.0 14.0 48.9
II 33.1 19.1 68.6
III 28.0 17.3 73.2
Cervical LN metastasisa 0.540 0.633 0.306
LN- 33.1 19.1 56.1
LN? 29.3 15.3 72.0
Perineural invasion 0.307 0.202 0.379
No 31.8 17.8 64.0
Yes 21.0 8.9 39.0
Tumor depth 0.217 0.828 0.006
\4 mm 35.7 14.0 39.3
C4 mm 29.3 16.6 72.0
Mortality related to tongue cancer (5 years) 0.964 0.319 0.065
No 31.8 14.0 48.9
Yes 31.8 19.1 71.4
Mortality related to other cause (5 years) 0.527 0.148 0.080
No 31.9 14.0 48.9
Yes 29.9 18.5 70.8
vWf indicates blood and lymphatic vessel density in microscopic field and podoplanin indicates lymphatic vessel density in microscopic field
(0.785 mm2/field; original magnification 2009). The relative density of lymphatic vessel (RDLV) indicates proportion of lymphatic vessels
(podoplanin) to all vessels (vWf)
RDVL the relative density of lymphatic vessels, y years
* p values by Mann–Whitney U test (dichotomous variables) and Kruskall–Wallis H’s test (continuous variables)
a Positive cervical lymph node metastasis (LN?) was determined by pN?; or cN? in the case of pNx
4520 Eur Arch Otorhinolaryngol (2016) 273:4515–4524
123
disease-specific survival (Fig. 2c, d) When observing the
subgroup without cervical lymph node metastasis, RDLV
C80 % associated significantly with poor overall sur-
vival, and insignificantly with poor disease-specific sur-
vival (Fig. 2e, f). In contrast, when observing the
subgroup of patients with cervical lymph node metasta-
sis, RDLV did not affect patients’ prognosis. In addition,
the same analysis was performed with the cut-off value
of C90 %, and even poorer survival rates were detected
(p B 0.001, data not shown). We also performed all
analyses with RDLV using cut-off values lower than
80 %. However, cut-off values not bring significant
difference to the survival rate. When we observed only
the intratumoral area, RDVL had no effect on patients’
survival. The mean density and diameter of lymphatic
vessels did not have an effect on patient survival, when
it was assessed in the whole tumor or in the intratumoral
area.
Cox regression analysis
Disease-specific survival was also tested for the following
12 factors by Cox regression: age, gender, smoking, heavy
alcohol abuse, previous lichen ruber planus, tumor size,
nodal metastasis, perineural invasion, lymphatic vessel
invasion, tumor depth, resection marginal, and RDLV. In
the unadjusted model, only the three following factors
associated significantly with tongue cancer death: tumor
size C20 mm (p = 0.044, OR 2.90, CI 1.03–8.18), the
presence of cervical metastasis (p = 0.021, OR 2.54, CI
1.15–5.62), and RDLV C80 % (p = 0.049, OR 2.27, CI
1.00–5.11). When analyzing these three factors in the same
Fig. 2 Relative density of
lymphatic vessel to all vessels
and survival curves of patients
with tongue cancer according to
the Kaplan–Meier method.
a Overall survival for the tongue
cancer patients (n = 61).
b Disease-specific survival for
the tongue cancer patients
(n = 49). c Overall survival for
the patients with primary tumor
size T1–T2 (n = 40).
d Disease-specific survival for
the patients with primary tumor
size T1–T2 (n = 33). e Overall
survival for the patients with
negative cervical lymph node
metastasis (LN-) (n = 38).
f Disease-specific survival for
the patients with LN- (n = 33).
LN- was determined by pN-;
or by cN- in the cases of pNx.
p-values by the log-rank test
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adjusted model, only RDLV C80 % associated signifi-
cantly with tongue cancer death (p = 0.050, OR 2.24, CI
1.00–5.02). Thus, the association of RDLV with tongue
cancer survival remained significant when adjusted by
cervical metastasis and tumor size.
Discussion
This study was implemented to evaluate lymphatic vessel
density and its predictive role in tongue cancer. The most
significant finding was that high RDLV (C80 %) associates
with poor survival in tongue cancer, as well as in the
subgroups with primary tumor size T1–T2 and non-
metastasized tongue cancer. High proportion of lymphatic
vessels might enable invasion of tongue cancer and thus
lead to patients’ poor outcome. Interestingly, we detected
an association between high depth of tumor invasion and
high proportion of lymphatic vessels. This is in line with
observations, that crosstalk between invasive tumor and
microenvironment might result in lymphangiogenesis [35].
We found that high RDLV did not affect patients’ survival
in the subgroup with metastatic tongue cancer. This might
be due to the fact that metastatic tongue cancer has overall
poorer prognosis than non-metastatic tongue cancer. To the
knowledge of the authors, RDLV in tongue cancer has not
previously been studied, and further studies in enlarged
sample size and other populations are required to prove the
results.
Despite the fact that the knowledge of the role of RDLV
in tongue cancer is minor, the absolute lymphatic vessels
density has previously been studied. We did not detect an
association between high lymphatic vessel density and
tongue cancer survival. The results of the predictive role of
lymphatic vessel density have been demonstrated to be
controversial also in other studies. A Japanese study group
performed VEGF-C immunostainings in oral cancer sam-
ples, and they demonstrated that high lymphatic vessel
density in whole tumor area predicts poor survival [36].
Another study group performed podoplanin immunostain-
ing in head and neck tumors, including samples from oral
cavity, oropharynx, and larynx, in population of Italy, and
showed that high peritumoral lymphatic vessel density
predicts poor survival [37]. On the other hand, another
study group performed podoplanin immunostaining in head
and neck tumors, including samples from oral cavity, lower
lip, and larynx, in population of Greece, and they did not
find a predictive role of peritumoral lymphatic vessel
density [38]. Furthermore, Mun˜oz-Guerra et al. stained oral
cancer specimens’ immunohistochemically by PA2.26, and
they suggested that high density of intratumoral lymphatic
vessels associates with poor prognosis [39]. In addition,
O’Donnell et al. studied population of the US and stained
oral cancer specimens’ immunohistochemically by podo-
planin. They detected that the number of intratumoral and
peritumoral lymphatic vessels is similar in oral cancer
[38, 40]. Our finding was that lymphatic vessels density in
intratumoral area is significantly higher than in whole
tumor. However, in our study, intratumoral lymphatic
vessel density did not affect patients’ survival. These
controversial results might be due to differences in the
populations, tumor locations, patient treatments, and
immunohistochemical or calculation techniques, such as
calculating vessels in intra- or peritumoral area. Thus, the
question of the role of the lymphatic vessels in tongue
cancer arises and requires additional studies.
Previous studies have indicated that the cells of the
immune system might prevent the cancer from spreading
through the blood vessels [20]. In addition, vWf might
have pro-apoptotic properties, and it might reduce metas-
tases by inducing tumor cell death [20, 22]. This could be
indirectly detected from our results, thus high proportion of
lymphatic vessels to all vessels predicts poor survival.
However, in our study, the vessels stained by vWf did not
predict better prognosis. Some other studies have suggested
that the interaction between tumor cells and coagulation
cascade factors (such as vWf) and/or platelets might pro-
mote invasiveness and metastasis capacity of cancer cells
[20, 41–44]. Hence, the role of blood and lymphatic vessels
in cancers remains unsolved, and additional studies are
needed.
Monoclonal anti-podoplanin, clone D2-40, is a reliable
lymphatic endothelial cell marker which identifies podo-
planin in lymphatic endothelium [24, 25, 45]. In many
cancers, the role of podoplanin has associated with tumor
progression and metastasis [46]. Several studies have
revealed altered podoplanin expression in various cancers,
including oral squamous cell carcinoma [46]. In addition,
previous studies have indicated the potential role of this
overexpressed protein in carcinogenesis, in hyperplastic
and dysplastic areas in oral mucosa [26, 32, 47]. Instead,
podoplanin expression has not been detected or was
extremely low in normal epithelium indicating its role in
tumorgenesis [26]. In this particular study, lymphatic ves-
sel density did not differ between tongue hyperplasia and
tongue cancer. Keeping this in mind, healthy tongue sam-
ples are also provided in future studies in cancer patho-
genesis and early diagnostics.
We acknowledge that the number of patients was
small, and that no healthy tongue tissue samples were
available in this study. These results should be confirmed
by a greater patient data and cross checked with healthy
control group. The proportion of lymphatic vessels to all
vessels might consume more time from the pathologist,
which might limit the clinical feasibility of RDLV as a
prognostic marker. On the other hand, microscopy might
4522 Eur Arch Otorhinolaryngol (2016) 273:4515–4524
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be easier based on our findings that RDLV can be
assessed from the whole sample instead of intratumoral or
peritumoral locations, which in some cases might be
difficult to differentiate. Due to the low number of
patients, we were not able to completely analyze the co-
effect of several factors.
As a conclusion, the density and diameter of lym-
phatic vessels were not associated with tongue cancer
survival. On the other hand, high relative density of
lymphatic vessels associates with tumor invasiveness and
poor survival. Further studies with increased population
size are still required to assess clinical relevancy of the
findings.
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